Noam Danenberg
CEO
Your CSV is on the way
We’ve sent your CSV file to email@email.com
Claimed by
owner Add to list
Wize Pharma
Former names: Star Night Technologies, OphthaliX
Treatments for Ophthalmic Disorders
Stealth Mode
by - on Mar 2021 - closed due to acquisition
Wize Pharma
Wize Pharma Overview
Wize Pharma is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES) and other inflammatory conditions.
Wize has in-licensed certain rights to purchase, market, sell, and distribute a formula known as LO2A, a drug developed for the treatment of DES and other ophthalmological illnesses, including CCH and Sjgrens syndrome. LO2A is currently registered and marketed in Germany and Switzerland for the treatment of DES; in Hungary for the treatment of DES, CCH, and Sjgrens; and in the Netherlands for the treatment of DES and Sjgrens.
Wizes strategy involves engaging local or multinational distributors to handle the distribution of LO2A. The company has finished a phase 2 trial of LO2A for patients with CCH and is currently conducting a phase 4 study of LO2A for DES in patients with Sjgrens.
LO2A was developed by Prof. Shabtay Dikstein of the Hebrew Universitys School of Pharmacy as a substitute for natural tears to lubricate and protect ocular surface tissues.
Wize has in-licensed certain rights to purchase, market, sell, and distribute a formula known as LO2A, a drug developed for the treatment of DES and other ophthalmological illnesses, including CCH and Sjgrens syndrome. LO2A is currently registered and marketed in Germany and Switzerland for the treatment of DES; in Hungary for the treatment of DES, CCH, and Sjgrens; and in the Netherlands for the treatment of DES and Sjgrens.
Wizes strategy involves engaging local or multinational distributors to handle the distribution of LO2A. The company has finished a phase 2 trial of LO2A for patients with CCH and is currently conducting a phase 4 study of LO2A for DES in patients with Sjgrens.
LO2A was developed by Prof. Shabtay Dikstein of the Hebrew Universitys School of Pharmacy as a substitute for natural tears to lubricate and protect ocular surface tissues.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Wize Pharma Climate Tech relevance
null
No Data, yet.
Sorry, no content found under this section.
Mar 24, 2021
www.prnewswire.com
Wize Pharma to change name to Mawson Infrastructure Group Inc.
#Acquisition
Feb 17, 2021
en.globes.co.il
Wize Pharma set for switch to Bitcoin mining
#Acquisition #Investment
Jan 1, 2021
en.globes.co.il
Wize Pharma merges with Australian Bitcoin miner Cosmos
#Acquisition #Investment
Nov 12, 2020
www.prnewswire.com
Wize Pharma Announces Positive Topline Results in Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome
#Customers
May 27, 2020
www.prnewswire.com
Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting on May 28-29, 2020
#Partners
Companies you might be interested in
Driven by Finder AI
Primary sector
Total funding
Funding stage
Number of employees
Founded
Related Content
Lists. Maps. Reports
Team Members
ND
GS
OE
DF
Contact Team
Affiliated Organizations
(null)Web & social links
https://www.wizepharma.com/
Locations
Israel
HaNagar Street 24, Hod Hasharon, Israel
Offices Abroad
Photos & videos
(2)No Data, yet.
Sorry, no content found under this section.
Wize Pharma
Wize Pharma1
Wize Pharma Business
Sector
Primary:
Health Tech & Life Sciences
Target Customer
Core Technology
Use Cases
(0)Tech Community Involvement
(0)Wize Pharma Financials
Cumulative Funding Raised Over Time ($)
No Data, yet.
Sorry, no content found under this section.
Public Offerings & Exits
Delisting
Mar 2021
Stock Exchange
Gvool Dotcom
M&A
Undisclosed
Mar 2021
Type
Acquisition
Was acquired by
-
Undisclosed
Initial Public Offering
EXIT
Undisclosed
Nov 2017
Stock Exchange
OTC
Valuation
Undisclosed
Undisclosed
Private Equity Funding
PIPE
$760K
Dec 2019
1
Investors
$760K
PIPE
$4.45M
Oct 2018
1
Investors
$4.45M
Non-Equity Funding
Mergers and Acquisitions
Wize Pharma Lifecycle
Cumulative Funding Raised Over Time ($)
Timeline
Employees Over Time
News Over Time
No Data, yet.
Sorry, no content found under this section.
Closing Event
Mar 2021
Delisting
Mar 2021
Stock Exchange
Gvool Dotcom
M&A
Undisclosed
Mar 2021
Type
Acquisition
Was acquired by
-
Undisclosed
PIPE
$760K
Dec 2019
1
Investors
$760K
PIPE
$4.45M
Oct 2018
1
Investors
$4.45M
Initial Public Offering
EXIT
Undisclosed
Nov 2017
Stock Exchange
OTC
Valuation
Undisclosed
Undisclosed
Wize Pharma News
News Over Time
No Data, yet.
Sorry, no content found under this section.
News Articles
Mar 24, 2021
www.prnewswire.com
Wize Pharma to change name to Mawson Infrastructure Group Inc.
#Acquisition
Feb 17, 2021
en.globes.co.il
Wize Pharma set for switch to Bitcoin mining
#Acquisition #Investment
Jan 1, 2021
en.globes.co.il
Wize Pharma merges with Australian Bitcoin miner Cosmos
#Acquisition #Investment
Nov 12, 2020
www.prnewswire.com
Wize Pharma Announces Positive Topline Results in Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome
#Customers
May 27, 2020
www.prnewswire.com
Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting on May 28-29, 2020
#Partners
Related Content
Wize Pharma Team
No Data, yet.
Sorry, no content found under this section.
Employees Over Time
Companies you might be interested in
Driven by Finder AI
Wize Pharma Internal
Create note
Notes
(undefined)
Filter notes
Content Writer
undefined
BI Verification
undefined
Phone Number
undefined
Israel Register ID
undefined
Confidence Score
undefined
Missing Fields
undefined
Profile Creator
undefined
Profile Update
undefined
undefined
Access Comprehensive Financial Analytics
Create a free account to:
- Explore detailed financial analytics.
- Track company growth and size.
- Connect with company team members.
I already have access,
I already have access,